Therapy Areas: Oncology
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
17 November 2025 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Monday that the US Food and Drug Administratio...
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
17 November 2025 - BodyLogicMD, a provider of bioidentical hormone replacement therapy (BHRT), integrative medicine and weight loss treatment, said on Friday that it completely supports the recommenda...
EirGenix signs second global exclusive licensing deal with Sandoz
13 November 2025 - Taiwan-based contract development and manufacturing organisation EirGenix Inc (TWSE:6589) announced on Wednesday that it has signed a second global exclusive licensing agreement wit...
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
12 November 2025 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Wednesday that the United States Patent and Trademark Office will issue U.S. Patent No. 12,472,205 on 18 Nove...
ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines
12 November 2025 - Danish clinical-stage biotechnology company ExpreS2ion Biotechnologies ApS, an affiliate of ExpreS2ion Biotech Holding AB (STO: EXPRS2), announced on Wednesday that it has signed a ...
Shilpa Medicare completes fourth complex clinical program with positive topline Phase three results for Shilpa's OERIS
12 November 2025 - India-based Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced on Tuesday that it has completed its fourth complex clinical program SMLINJ011, with positive topline Ph...